AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Jasper Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Magnachip Semiconductor Corp. (MX) filed a Form 4 disclosing that director Ilbok Lee acquired 55,845 shares of common stock on July 1 2025. The transaction was coded "A" (acquisition) and carries a stated price of $0, indicating a grant, award or other non-cash issuance. Following the transaction, Lee’s direct ownership increased to 275,026 shares. No derivative securities were involved, and there were no dispositions.

The filing signals a meaningful expansion of an insider’s equity stake and may be interpreted by investors as a vote of confidence in the company’s prospects.

Magnachip Semiconductor Corp. (MX) ha presentato un Modulo 4 rivelando che il direttore Ilbok Lee ha acquisito 55.845 azioni ordinarie il 1 luglio 2025. L'operazione è stata classificata come "A" (acquisizione) e riporta un prezzo dichiarato di 0 $, indicando una concessione, premio o altra emissione non monetaria. Dopo questa transazione, la proprietà diretta di Lee è aumentata a 275.026 azioni. Non sono stati coinvolti titoli derivati e non ci sono state cessioni.

La comunicazione segnala un significativo aumento della partecipazione azionaria di un insider e può essere interpretata dagli investitori come un segnale di fiducia nelle prospettive dell'azienda.

Magnachip Semiconductor Corp. (MX) presentó un Formulario 4 revelando que el director Ilbok Lee ²¹»å±ç³Ü¾±°ù¾±Ã³ 55,845 acciones ordinarias el 1 de julio de 2025. La transacción fue codificada como "A" (adquisición) y tiene un precio declarado de $0, lo que indica una concesión, premio u otra emisión no monetaria. Tras la operación, la propiedad directa de Lee aumentó a 275,026 acciones. No se involucraron valores derivados y no hubo disposiciones.

La presentación señala una expansión significativa de la participación accionaria de un insider y puede interpretarse por los inversores como un voto de confianza en las perspectivas de la compañía.

Magnachip Semiconductor Corp. (MX)ëŠ� ì´ì‚¬ Ilbok Leeê°¶Ä 2025ë…� 7ì›� 1ì�ì—� 55,845ì£� 보통ì£�ë¥� ì·¨ë“했다ê³� ì‹ ê³ í•� Form 4ë¥� 제출했습니다. 거래ëŠ� "A"(ì·¨ë“)ë¡� 분류ë˜ì—ˆê³� 명시ë� ê°¶Äê²©ì€ $0ë¡�, ì´ëŠ” ë¶€ì—�, ìƒê¸ˆ ë˜ëŠ” 기타 현금ì� 아닌 발행ì� ì˜ë¯¸í•©ë‹ˆë‹�. ì� 거래 í›� ì´ì”¨ì� ì§ì ‘ 소유 주ì‹ì€ 275,026ì£�ë¡� ì¦ê°¶Ä했습니ë‹�. íŒŒìƒ ì¦ê¶Œì€ í¬í•¨ë˜ì§€ 않았으며 처분ë� 없었습니ë‹�.

ì� ì‹ ê³ ëŠ� ë‚´ë¶€ìžì˜ ì§€ë¶� 확대ë¥� ì˜ë¯¸í•˜ë©° 투ìžìžë“¤ì—게 회사 ì „ë§ì—� 대í•� 신뢰ì� 표시ë¡� í•´ì„ë� ìˆ� 있습니다.

Magnachip Semiconductor Corp. (MX) a déposé un formulaire 4 révélant que le directeur Ilbok Lee a acquis 55 845 actions ordinaires le 1er juillet 2025. La transaction a été codée "A" (acquisition) et affiche un prix déclaré de 0 $, indiquant une attribution, une récompense ou une autre émission non monétaire. Suite à cette opération, la détention directe de Lee est passée à 275 026 actions. Aucun titre dérivé n’a été impliqué et aucune cession n’a eu lieu.

Cette déclaration signale une augmentation significative de la participation d’un initié et peut être interprétée par les investisseurs comme un vote de confiance dans les perspectives de la société.

Magnachip Semiconductor Corp. (MX) hat ein Formular 4 eingereicht, das offenlegt, dass Direktor Ilbok Lee am 1. Juli 2025 55.845 Stammaktien erworben hat. Die Transaktion wurde mit "A" (Erwerb) codiert und weist einen angegebenen Preis von 0 $ auf, was auf eine Zuteilung, Auszeichnung oder andere nicht monetäre Ausgabe hinweist. Nach der Transaktion erhöhte sich Lees Direktbesitz auf 275.026 Aktien. Es waren keine Derivate beteiligt und es gab keine Veräußerungen.

Die Meldung signalisiert eine bedeutende Erweiterung der Aktienbeteiligung eines Insiders und kann von Investoren als Vertrauensbeweis in die Aussichten des Unternehmens interpretiert werden.

Positive
  • Director Ilbok Lee acquired 55,845 common shares, increasing his stake to 275,026 shares, a roughly 25% rise in personal ownership.
  • No shares were sold, reinforcing a net increase in insider holdings and a potentially positive signal to the market.
Negative
  • None.

Insights

TL;DR: Director added 55.8K shares, raising stake to 275K—generally a bullish insider signal.

The Form 4 shows director Ilbok Lee receiving 55,845 Magnachip shares via a zero-cost grant on 1 July 2025. The award lifts his direct holdings by roughly 25% (from ~219k to 275k shares), aligning his interests more closely with shareholders. Although the transaction is not an open-market purchase, the larger ownership position still reflects confidence and can reduce agency risk. No sales or derivative activity were reported, and the filing contains no adverse disclosures. Overall impact is modestly positive for sentiment but has limited financial effect given the company’s ~38 million shares outstanding.

Magnachip Semiconductor Corp. (MX) ha presentato un Modulo 4 rivelando che il direttore Ilbok Lee ha acquisito 55.845 azioni ordinarie il 1 luglio 2025. L'operazione è stata classificata come "A" (acquisizione) e riporta un prezzo dichiarato di 0 $, indicando una concessione, premio o altra emissione non monetaria. Dopo questa transazione, la proprietà diretta di Lee è aumentata a 275.026 azioni. Non sono stati coinvolti titoli derivati e non ci sono state cessioni.

La comunicazione segnala un significativo aumento della partecipazione azionaria di un insider e può essere interpretata dagli investitori come un segnale di fiducia nelle prospettive dell'azienda.

Magnachip Semiconductor Corp. (MX) presentó un Formulario 4 revelando que el director Ilbok Lee ²¹»å±ç³Ü¾±°ù¾±Ã³ 55,845 acciones ordinarias el 1 de julio de 2025. La transacción fue codificada como "A" (adquisición) y tiene un precio declarado de $0, lo que indica una concesión, premio u otra emisión no monetaria. Tras la operación, la propiedad directa de Lee aumentó a 275,026 acciones. No se involucraron valores derivados y no hubo disposiciones.

La presentación señala una expansión significativa de la participación accionaria de un insider y puede interpretarse por los inversores como un voto de confianza en las perspectivas de la compañía.

Magnachip Semiconductor Corp. (MX)ëŠ� ì´ì‚¬ Ilbok Leeê°¶Ä 2025ë…� 7ì›� 1ì�ì—� 55,845ì£� 보통ì£�ë¥� ì·¨ë“했다ê³� ì‹ ê³ í•� Form 4ë¥� 제출했습니다. 거래ëŠ� "A"(ì·¨ë“)ë¡� 분류ë˜ì—ˆê³� 명시ë� ê°¶Äê²©ì€ $0ë¡�, ì´ëŠ” ë¶€ì—�, ìƒê¸ˆ ë˜ëŠ” 기타 현금ì� 아닌 발행ì� ì˜ë¯¸í•©ë‹ˆë‹�. ì� 거래 í›� ì´ì”¨ì� ì§ì ‘ 소유 주ì‹ì€ 275,026ì£�ë¡� ì¦ê°¶Ä했습니ë‹�. íŒŒìƒ ì¦ê¶Œì€ í¬í•¨ë˜ì§€ 않았으며 처분ë� 없었습니ë‹�.

ì� ì‹ ê³ ëŠ� ë‚´ë¶€ìžì˜ ì§€ë¶� 확대ë¥� ì˜ë¯¸í•˜ë©° 투ìžìžë“¤ì—게 회사 ì „ë§ì—� 대í•� 신뢰ì� 표시ë¡� í•´ì„ë� ìˆ� 있습니다.

Magnachip Semiconductor Corp. (MX) a déposé un formulaire 4 révélant que le directeur Ilbok Lee a acquis 55 845 actions ordinaires le 1er juillet 2025. La transaction a été codée "A" (acquisition) et affiche un prix déclaré de 0 $, indiquant une attribution, une récompense ou une autre émission non monétaire. Suite à cette opération, la détention directe de Lee est passée à 275 026 actions. Aucun titre dérivé n’a été impliqué et aucune cession n’a eu lieu.

Cette déclaration signale une augmentation significative de la participation d’un initié et peut être interprétée par les investisseurs comme un vote de confiance dans les perspectives de la société.

Magnachip Semiconductor Corp. (MX) hat ein Formular 4 eingereicht, das offenlegt, dass Direktor Ilbok Lee am 1. Juli 2025 55.845 Stammaktien erworben hat. Die Transaktion wurde mit "A" (Erwerb) codiert und weist einen angegebenen Preis von 0 $ auf, was auf eine Zuteilung, Auszeichnung oder andere nicht monetäre Ausgabe hinweist. Nach der Transaktion erhöhte sich Lees Direktbesitz auf 275.026 Aktien. Es waren keine Derivate beteiligt und es gab keine Veräußerungen.

Die Meldung signalisiert eine bedeutende Erweiterung der Aktienbeteiligung eines Insiders und kann von Investoren als Vertrauensbeweis in die Aussichten des Unternehmens interpretiert werden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lucas Svetlana

(Last) (First) (Middle)
C/O JASPER THERAPEUTICS, INC.
2200 BRIDGE PKWY, SUITE #102

(Street)
REDWOOD CITY CA 94065

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc. [ JSPR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $6.77 07/03/2025 A 7,500(1) 07/03/2026 07/03/2035 Voting Common Stock 7,500 $0.00 7,500 D
Explanation of Responses:
1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders.
By: /s/ Herb Cross, as Attorney-in-Fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Magnachip (MX) shares did Director Ilbok Lee acquire?

He acquired 55,845 shares of common stock.

What is Ilbok Lee’s total Magnachip shareholding after the transaction?

Following the grant, he directly owns 275,026 shares.

When did the insider acquisition occur?

The transaction date is listed as July 1 2025 on Form 4.

Was any cash paid for the shares?

The Form 4 indicates a $0 purchase price, suggesting the shares were granted rather than bought on the open market.

Were any derivative securities reported in this filing?

No, Table II shows no derivative securities acquired or disposed of.
Jasper Therapeutics Inc

NASDAQ:JSPR

JSPR Rankings

JSPR Latest News

JSPR Latest SEC Filings

JSPR Stock Data

83.37M
14.83M
1.26%
105.27%
13.82%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
REDWOOD CITY